Streamlined Path for Advanced Therapies
Dark Horse Consulting Group and Porton Advanced have entered into a strategic Memorandum of Understanding (MOU) to facilitate Investigator-Initiated Trials (IITs) in China. Announced on April 26, 2026, this collaboration is poised to accelerate the global development of cell and gene therapies.
The collaboration combines Dark Horse's extensive expertise in regulatory affairs, clinical strategies, and business analytics with Porton Advanced's robust manufacturing capabilities. These capabilities include Good Manufacturing Practice (GMP) production of advanced therapy medicinal products such as lentiviral vectors, AAV, mRNA/LNP, plasmids, and engineered cell therapies like CAR-T, CAR-NK, and iPSC-derived products.
Anthony Davies, Ph.D., CEO of Dark Horse Consulting Group, emphasised the partnership, noting it offers a "streamlined pathway for client partners interested in undertaking an IIT in China," significantly reducing the time to first-in-human trials. This is especially crucial for programmes targeting the rapidly expanding Chinese market.
Expanding Global Reach
Porton Advanced supports a wide array of therapies, including CAR-T and mRNA, and holds 24 Investigational New Drug (IND) clearances from both the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). With its extensive experience, the collaboration aims to tackle regulatory and manufacturing hurdles, offering a more efficient route for clinical-stage manufacturing in China.
Andrew Chen, CEO of Porton Advanced, highlighted the synergy between the two organisations, stating that the partnership provides "a genuinely differentiated offering for developers at every stage." This collaboration will enable sponsors and investigators to advance their programmes with greater speed and confidence, minimizing delays typically encountered at the manufacturing-regulatory interface.
The partnership is a response to the growing demand for IIT-enabling services in China, considered one of the most significant markets for advanced therapies. By combining their strengths, Dark Horse Consulting Group and Porton Advanced aim to facilitate a smoother process for international sponsors seeking to conduct trials in the region, helping developers bring therapies to patients faster.
This agreement reflects a commitment to addressing the challenges faced in the clinical translation of innovative therapies, focusing on reducing friction at the manufacturing-regulatory interface. The partnership's emphasis on enabling Investigator-Initiated Trials is expected to open new avenues for the development and commercialization of advanced therapies globally.
Last updated: 27 April 2026, 9:19 pm
